Abstract:Purpose: A dearth in pediatric drug development often leaves pediatricians with no alternative but to prescribe unlicensed or off-label drugs with a resultant increased risk of adverse events. We present the current status of pediatric drug development and, based on our data analysis, clarify the problems in this area. Further action is proposed to improve the drug development that has pediatric therapeutic orphan status. Methods: We analyzed all Phase II/III and Phase III trials in ClinicalTrials.gov that only included pediatric participants (<18 years old) between 2006 and 2014. Performance index, an indicator of pediatric drug development, was calculated by dividing the annual number of pediatric clinical trials by million pediatric populations acquired from Census.gov. Effects of the 2 Japanese premiums introduced in 2010, for the enhancement of pediatric drug development, were analyzed by comparing mean performance index prepremiums (2006-2009) and postpremiums (2010-2014) among Japan, the European Union, and the United States. The European Union Clinical Trials Register and published reports from the European Medicines Agency were also surveyed to investigate the Paediatric Committee effect on pediatric clinical trials in the European Union. Findings: Mean difference of the performance index in prepremiums and postpremiums between Japan and the European Union were 0.296 (P < 0.001) and 0.066 (P = 0.498), respectively. Those between Japan and the United States were 0.560 (P < 0.001) and 0.281 (P = 0.002), indicating that pediatric drug development in Japan was more active after the introduction of these premiums, even reaching the level of the European Union. The Pediatric Regulation and the Paediatric Committee promoted pediatric drug development in the European Union. The registered number of clinical trials that includes at least 1 participants <18 years old in the European Union Clinical Trials Register increased by 247 trials (from 672) in the 1000 days after regulation. The ratio of pediatric clinical trials with an approved Paediatric Investigation Plan increased to >15% after 2008. Implications: Recruitment and ethical obstacles make conducting pediatric clinical trials challenging. An improved operational framework for conducting clinical trials should mirror the ever-improving regulatory framework that incentivizes investment in pediatric clinical trials. Technological approaches, enhancements in electronic medical record systems, and community approaches that actively incorporate input from physicians, researchers, and patients could offer a sustainable solution to recruitment of pediatric study participants. The key therefore is to improve pediatric pharmacotherapy collaboration among industry, government, academia, and community. Expanding the regulatory steps taken in the European Union, United States, and Japan and using innovative clinical trial tools can move pediatric pharmacotherapy out of its current therapeutic orphan state.

Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children

Innovative study design for paediatric clinical trials

General Clinical and Methodological Considerations on the Extrapolation of Pharmacokinetics and Optimization of Study Protocols for Small Molecules and Monoclonal Antibodies in Children

Pharmacokinetic and pharmacodynamic principles: unique considerations for optimal design of neonatal clinical trials

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks

Dosage individualization in children: integration of pharmacometrics in clinical practice

BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials

Novel Design and Analysis for Rare Disease Drug Development

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

New Horizons in Pediatric Psychopharmacology

Pediatric oncology drug development and dosage optimization

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Current Knowledge, Challenges and Innovations in Developmental Pharmacology: A Combined Conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

Principles and Applications of Pharmacometrics in Drug Evaluation in Children.

Paediatric Drug Development and Formulation Design—a European Perspective

Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies